文献速递生殖医学

孕激素主导卵巢刺激在玻璃化供卵周期中提供与GnRH拮抗剂相当结局

Progestin prime ovarian stimulation provides comparable outcomes to GnRH antagonist in donor cycles with vitrified oocytes.
PubMed 文献 · Fertil Steril · 2025-05-20

回顾性队列研究纳入14,981名接受玻璃化供卵的受者,比较供者使用醋酸甲羟孕酮(MPA)与促性腺激素释放激素拮抗剂(GnRHant)方案的结局。MPA组卵母细胞复苏存活率和囊胚形成率显著更高,但着床率、临床妊娠率、持续妊娠率和累积活产率两组相当。GEE模型显示垂体抑制方案类型对活产率无显著影响(比值比1.09,95%置信区间0.97-1.23)。

要点

  • MPA组卵母细胞复苏存活率90.17% vs GnRHant组88.41%,囊胚形成率57.58% vs 53.99%。
  • 两组着床率、临床妊娠率、持续妊娠率及累积活产率均无显著差异。
  • GEE模型显示垂体抑制方案类型对活产率无显著影响(比值比1.09,95%置信区间0.97-1.23)。

核心结论

  • 醋酸甲羟孕酮(MPA)方案与GnRHant方案在玻璃化供卵周期中产生相当的临床结局。
  • 基于人工智能的评估显示两种方案间卵母细胞和胚胎质量无显著差异,与临床结局一致。
  • 结果支持MPA作为供卵玻璃化周期中经济、患者友好的替代方案。

研究设计与样本

  • 回顾性队列研究,纳入14,981名接受玻璃化供卵的受者,供者来自3,599名接受MPA刺激和4,998名接受GnRHant刺激的供者。
  • 暴露因素为卵巢刺激期间使用MPA或GnRHant方案进行垂体抑制。
  • 主要结局指标包括着床率、临床妊娠率、持续妊娠率和累积活产率,非临床指标包括基于人工智能的卵母细胞和胚胎质量评分。

主要发现

  • MPA组卵母细胞复苏后存活率显著高于GnRHant组(90.17% vs 88.41%)。
  • MPA组囊胚形成率显著高于GnRHant组(57.58% vs 53.99%)。
  • 基于人工智能的卵母细胞评分(5.9 ± 2.8 vs 6.0 ± 2.9)和胚胎评分(5.0 ± 2.6 vs 5.1 ± 2.7)两组无显著差异。
  • 着床率(57.68% vs 55.82%)、临床妊娠率(58.17% vs 58.14%)、持续妊娠率(49.40% vs 48.15%)和累积活产率(65.60% vs 65.50%)两组相当。
  • 对同时接受两种方案刺激的供者进行配对分析支持上述发现,临床结局无显著差异。

临床怎么用

  • 作者认为结果支持MPA作为供卵玻璃化周期中经济、患者友好的替代方案,为临床应用提供了有力证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effectiveness and safety of medroxyprogesterone acetate (MPA) and gonadotropin-releasing hormone antagonist (GnRHant) protocols in vitrified donor oocyte cycles and expand the current evidence on their clinical outcomes. DESIGN: Retrospective cohort study. SUBJECTS: This study included 14,981 recipients who received vitrified oocytes coming from 3,599 donors stimulated with MPA and 4,998 donors stimulated with GnRHant. EXPOSURE: Pituitary suppression during ovarian stimulation with either MPA or GnRHant protocols. MAIN OUTCOME MEASURES: Clinical metrics included implantation, clinical pregnancy rate, ongoing pregnancy rate and cumulative live birth rate. Nonclinical metrics included artificial intelligence (AI)-based oocyte and embryo quality scores. RESULTS: The MPA group demonstrated significantly higher oocyte survival rates postwarming (90.17% vs. 88.41%) and blastocyst formation rates (57.58% vs. 53.99%) compared with the GnRHant group. Artificial intelligence-based evaluations revealed no significant differences in oocyte (5.9 ± 2.8 vs. 6.0 ± 2.9) or embryo (5.0 ± 2.6 vs. 5.1 ± 2.7) scores between the 2 groups. Clinical outcomes, including implantation rate (57.68% vs. 55.82%), clinical pregnancy rate (58.17% vs. 58.14%), ongoing pregnancy rate (49.40% vs. 48.15%) and cumulative live birth rate (65.60% vs. 65.50%), were comparable between MPA and GnRHant protocols. The paired analysis of donors stimulated with both protocols supported these findings, showing no significant differences in clinical outcomes. Finally, the Generalized Estimating Equations (GEEs) model identified significant predictors of live birth, including recipient age, recipient body mass index (BMI), number of metaphase II (MII) oocytes, embryo quality, and the number of warmed MII oocytes, whereas the type of pituitary suppression protocol (MPA vs. GnRHant) did not significantly impact live birth rates (odds ratio: 1.09 [95% confidence interval: 0.97-1.23]). CONCLUSION: Medroxyprogesterone acetate and GnRHant protocols yielded comparable clinical outcomes in vitrified donor oocyte cycles. Artificial intelligence-based assessments showed consistency with clinical outcomes, detecting no significant differences in oocyte or embryo quality between protocols. These results support the use of MPA as a cost-effective, patient-friendly alternative in donor oocyte vitrification cycles, providing robust evidence for its clinical application.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Murria L, Giles J, Bori L, et al. Progestin prime ovarian stimulation provides comparable outcomes to GnRH antagonist in donor cycles with vitrified oocytes. Fertil Steril. 2025. PMID: 40403912. doi:10.1016/j.fertnstert.2025.05.154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。